The readout suggests that, if anything, adding tremelimumab to PD-L1 drug Imfinzi results in worse outcomes in metastatic NSCLC.

Dermavant hires Zavodnick as CEO; Bayer VP to lead Matoke Pharma; and Genentech I-O leader Wei Lin will head up Nektar's oncology work.

Tocagen has named Lori Kunkel as its acting CMO after the departure of Asha Das, who is leaving because of “immediate personal matters.”

RenalytixAI will advance two AI-based tests: one to spot kidney disease early, and another to manage rejection in transplant patients.

AbbVie and Mission Therapeutics inked an R&D pact focused on deubiquitylating enzymes in Alzheimer’s and Parkinson’s disease.

In a collaboration worth up to $300 million or more, Boehringer Ingelheim tapped Epizyme to help research two regulators of genes linked to cancer.

Arena’s run of positive news continues, with a massive $800 million upfront deal with United for pulmonary arterial hypertension drug ralinepag.

Real-world data firm Litmus Health published its first census of wearable devices for clinical research.

The FIX-Padua therapy achieved FIX activity levels of 23% to 37%, suggesting it is several times more effective than unIQure's old asset.